Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, Kansas 66612-1220

Kansas Department of Health and Environment

Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Lee A. Norman, M.D., Secretary

Laura Kelly, Governor

Drug Utilization Review Board Meeting
Agenda, Open Session July 8, 2020
10:00 a.m. – 2:00 p.m.

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:
Public Dial: (833) 649-1465. Conference ID: 5062278. To view the meeting, use the following WebEx link:
https://intercall.webex.com/intercall/j.php?MTID=ma5bb26d38ffde5d7873426fdd8e3d0da
Please note: Audio is disabled on the WebEx. Audio will only be available on the Public Dial.

Members of the general public are required to complete a conflict of interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (July 1, 2020). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD
James Backes, PharmD
Jennifer Clair, MD
Katie Burenheide Foster, PharmD, MS, BCPS, FCCM
Kristen Powell, PharmD
Serena Stutzman, APRN
Roger Unruh, DO
LaTonyua Rice, PharmD, CGP
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD

DXC Technology/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Ariane Casey, PharmD
Harry Vu, PharmD

MCO Staff

Alan Carter, PharmD, **Aetna Better Health of Kansas**
Angie Yoo, PharmD, **Sunflower State Health Plan**
Jan Mueller, RPh, **UnitedHealthcare Community Plan**

I. CALL TO ORDER

A. Announcements

1. This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of January 8, 2020 Meeting Minutes

III. NEW BUSINESS

A. New Preferred Drug List (PDL) Classes

1. **Acne Agents - Isotretinoin Products**
   At the March 2020 PDL meeting, the committee approved the addition of Acne Agents - Isotretinoin Products to the PDL. Standard non-preferred prior authorization criteria are being proposed for this new class to allow access to non-preferred agents.
   i. Non-Preferred PDL PA Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Colchicine Products - Gout Prophylaxis**
   At the March 2020 PDL meeting, the committee approved the addition of Colchicine Products - Gout Prophylaxis to the PDL. Standard non-preferred prior authorization criteria are being proposed for this new class to allow access to non-preferred agents.
   i. Non-Preferred PDL PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **SGLT2 Inhibitor/DPP-4 Inhibitor/Biguanide**
   At the March 2020 PDL meeting, the committee approved the addition of SGLT2 Inhibitor/DPP-4 Inhibitor/Biguanide to the PDL. Standard non-preferred prior authorization criteria are being proposed for this new class to allow access to non-preferred agents.
   i. Non-Preferred PDL PA Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **Consent Agenda - Biosimilars**
   At the March 2020 PDL meeting, the committee approved to further expand the PDL Consent Agenda Criteria. Biosimilars having the same FDA-approved indication as the reference drug may be added using this process.
   i. Non-Preferred PDL PA Criteria
   ii. *Public Comment
   iii. Board Discussion

B. Mental Health Medication Advisory Committee (MHMAC)

1. **Antidepressant Medications – Safe Use for All Ages**
   At the February 2020 MHMAC meeting, the committee revised the criteria for use of Antidepressant Medications – Safe Use for All Ages prior authorization (PA), to include Spravato® and include the PHQ-9 depression rating scale.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Antidepressant Medications – Safe Use for All Ages**
   At the May 2020 MHMAC meeting, the committee further revised the criteria for use of Antidepressant Medications – Safe Use for All Ages PA to include a dosing table.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Antipsychotic Medications - Safe Use for All Ages**
   At the February 2020 MHMAC meeting, the committee revised the criteria for use of Antipsychotic Medications – Safe Use for All Ages PA to include Secuado® and Caplyta®. Step therapy was also revised.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **ADHD Medications – Safe Use for All Ages**
   At the May 2020 MHMAC meeting, the committee revised the criteria for use of ADHD Medications – Safe Use for All Ages PA to include Adhansia XR™.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **RDUR Criteria – Further Review**
   At the May 2020 MHMAC meeting, the committee approved Retrospective Drug Utilization Review criteria for mental health medications. Patients taking multiple concurrent mental health medications will be reviewed on a regular basis. These criteria indicate the need for further review with a plan psychiatrist.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

C. Prioritized Agenda Items

1. **Migraine – Prophylaxis Agents –** New PA Criteria
   These criteria will combine and supersede the criteria for Botulinum Toxins, the CGRP Antagonists, and the Topiramate ER criteria for agents used for the prophylaxis of migraines. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information, clinical guidelines, and step therapy.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Botulinum Toxins –** Revised PA Criteria
   This revision modifies PA criteria to carve out the migraine indications. A separate PA criteria for migraine prophylaxis will be created. Indication updates were made to Botox®, Myobloc®, and Myobloc®.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Migraine – Acute Treatment Agents –** New Criteria
   Multiple new agents now exist for the acute treatment of migraines. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information, clinical guidelines, and step therapy.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **Type 2 Diabetes Mellitus (T2DM) Agents –** Revised PA Criteria
   This revision modifies PA criteria to combine and supersede the Metformin ER and Diabetic Agents criteria and update to the new PA format. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **Opioid Products Indicated for Pain Management –** Revised Criteria
   This revision modifies PA criteria to clarify that active pharmaceutical ingredients (APIs) are not managed on this PA criteria. This also clarifies that the considerations for MME calculations generally exclude injectables and cough/cold products that contain opioids, similar to the CDC's inclusion and exclusion criteria.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

6. **Duchenne Muscular Dystrophy (DMD) Agents –** New Criteria
   These criteria will combine and supersede the Emflaza® and Exondys 51® criteria for agents used for the treatment of Duchenne muscular dystrophy. These prior authorization criteria include step therapy, adds Vyondys 53™, and are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

7. **Advanced Medical Hold Manual Review (AMHMR)**
   This revision is to update the drug selection group in the Manual Guidelines section.
   i. *Public Comment
   ii. Board Discussion

8. **Fee-for-Service Retrospective Drug Utilization Review Topic Selections**
   The DUR Board will select topics, for the two (2) FFS RDUR interventions between July and September 2020.
   i. Topic Presentations
   ii. Board Discussion

D. Additional Agenda Items (as time allows)

1. **Minimum Requirements Prior Authorization –** Updated Drug List
   This revision adds the following agents: Arikayce®, Epidiolex®, Onfi®, Sympazan™, Neudexta®, Viberzi™, Increlex®, Ofev®, Osphena®, Esbriet®, Banzel®, Vesicare LS™, Diacomit®, and Xermelo™
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Atopic Dermatitis (AD) Agents –** Revised Criteria
   This revision modifies PA criteria to clarify the use of conventional agents and to update indications for Eucrisa® and Dupixent®.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Codeine Products in Children**
   Request for an age limitation edit at the point-of-sale for codeine products used in children.
   i. *Public Comment
   ii. Board Discussion

4. **Ulcerative Colitis (UC) Agents –** Revised Criteria
   This revision modifies PA criteria to adjust step therapy for Xeljanz®/Xeljanz® XR, add Stelara®, and to add the biosimilars Abrilada™ and Avsola™.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **Plaque Psoriasis (PsO) Agents –** Revised Criteria
   This revision modifies PA criteria to update changes to Taltz™ indication and add biosimilars Hadlima™, Abrilada™, and Avsola™.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

6. **Hepatitis C Agents –** Revised Criteria
   This revision modifies PA criteria to update changes to Epclusa® indication, clarify treatment experience for Sovaldi® and Harvoni®, and add NS5A testing for Zepatier®.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

7. **Multiple Sclerosis (MS) Agents –** Revised Criteria
   This revision modifies PA criteria to update changes to Glatopa® dosing, and add two additional FDA-approved agents, Bafiertam® and Zeposia®.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

IV. OPEN PUBLIC COMMENT

V. ADJOURN

The next DUR Board meeting is scheduled for October 14, 2020.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****